CN Patent

CN106794185A — Rucaparib的高剂量强度片剂

Assigned to Clovis Oncology Inc · Expires 2017-05-31 · 9y expired

What this patent protects

本发明公开包含高剂量的8‑氟‑2‑{4‑[(甲基氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂 并[5,4,3‑cd]吲哚‑6‑酮樟脑磺酸盐的片剂。本发明涉及rucaparib的高剂量强度片剂。在一些实施方案中，所述片剂包含45‑90％w/w的rucaparib樟脑磺酸盐。在一些实施方案中，所述干法制粒片剂包含45‑90％w/w的rucaparib樟脑磺酸盐。一个这样的实施方案是包含至少200mg rucaparib的片剂。另一实施方案是包含至少300mg rucaparib的片剂。

USPTO Abstract

本发明公开包含高剂量的8‑氟‑2‑{4‑[(甲基氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂 并[5,4,3‑cd]吲哚‑6‑酮樟脑磺酸盐的片剂。本发明涉及rucaparib的高剂量强度片剂。在一些实施方案中，所述片剂包含45‑90％w/w的rucaparib樟脑磺酸盐。在一些实施方案中，所述干法制粒片剂包含45‑90％w/w的rucaparib樟脑磺酸盐。一个这样的实施方案是包含至少200mg rucaparib的片剂。另一实施方案是包含至少300mg rucaparib的片剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN106794185A
Jurisdiction
CN
Classification
—
Expires
2017-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Clovis Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.